Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 11:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Lung Neoplasms, Carcinoma Non-small-cell Lung
Interventions: Multifocal Tissue Banking; Genetic
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Opioid-Related Disorders
Interventions: Buprenorphine; Drug
Lead sponsor: Yale University; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1988 – 2006
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Autism, Autism Spectrum Disorder
Interventions: Charades based mobile digital therapeutic; Device
Lead sponsor: Stanford University; Other
Eligibility: 3 Years to 12 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Small Cell Lung Cancer
Interventions: Pembrolizumab 200 mg, Pembrolizumab 400 mg, Pembrolizumab placebo (saline), Olaparib 300 mg BID, Olaparib matching placebo, Etoposide 100 mg/m^2, Platinum, investigator's choice, Standard Thoracic Radiotherapy, Prophylactic Cranial Irradiation (PCI); Biological · Drug · Radiation
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 35
States / cities: Chandler, Arizona • Loma Linda, California • Washington D.C., District of Columbia + 29 more

Conditions: Preventive Screening, Prostate Cancer, Osteoporosis, Colorectal Cancer
Interventions: Quantitative Information Sheet, Qualitative Information Sheet, Narrative Information Sheet, Framed Information Sheet; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 50 Years to 85 Years
Enrollment: 775 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: End Stage Renal Disease (ESRD)
Interventions: Acellular Tissue Engineered Vessel (ATEV), AVF; Biological · Other
Lead sponsor: Humacyte, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 32
States / cities: Scottsdale, Arizona • El Centro, California • La Jolla, California + 25 more

Conditions: HIV, Hepatitis C, Hepatitis B, Syphilis
Interventions: Rapid tests for HIV, HCV, HBV, and syphilis, HIV/HCV, HIV/syphilis, HIV only; Device
Lead sponsor: California State University, Long Beach; Other
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Cardiovascular Diseases
Interventions: Point of Care, Population Management; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 5
States / cities: Chicago, Illinois • DeKalb, Illinois • Oak Brook, Illinois + 2 more

Conditions: Anogenital Herpes, COVID-19, Herpes Labialis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 120 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Disease
Interventions: Voxelotor, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years to 14 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 13
States / cities: Washington D.C., District of Columbia • Miami, Florida • Atlanta, Georgia + 5 more

Conditions: Multiple Sclerosis
Interventions: Constraint-Induced Movement Therapy; Behavioral
Lead sponsor: National Multiple Sclerosis Society; Other
Eligibility: 21 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Osteoarthritis, Knee
Interventions: Hylan F- 20; Drug
Lead sponsor: Steadman Hawkins Research Foundation; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Vail, Colorado

Conditions: Giant Cell Arteritis
Interventions: Sirukumab, Placebo to match sirukumab, Prednisone, Placebo to match prednisone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 13
States / cities: Aurora, Colorado • Boca Raton, Florida • Naples, Florida + 9 more

Conditions: Diffuse Cutaneous Systemic Sclerosis
Interventions: Patients will be randomized to receive EHP-101 or Placebo; Drug
Lead sponsor: Emerald Health Pharmaceuticals; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 13
States / cities: Phoenix, Arizona • Huntington Beach, California • Los Angeles, California + 9 more

Conditions: Prostate Cancer
Interventions: UreScan; Device
Lead sponsor: University of California, Irvine; Other
Eligibility: 40 Years to 80 Years · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Orange, California

Conditions: Bacterial Infection
Interventions: ceftaroline, linezolid, Aztreonam; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 13
States / cities: Buena Park, California • Long Beach, California • Los Angeles, California + 10 more

Conditions: HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions: pegylated liposomal doxorubicin hydrochloride, cyclophosphamide, trastuzumab; Drug · Biological
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
Interventions: CD30.CAR-T; Drug
Lead sponsor: Tessa Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2036
U.S. locations: 4
States / cities: Duarte, California • Nashville, Tennessee • Houston, Texas

Conditions: Alcohol Abuse
Interventions: Youth Access; Behavioral
Lead sponsor: Oregon Research Institute; Other
Eligibility: 13 Years to 19 Years
Enrollment: 7,379 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Hearing Loss
Interventions: Programmable directional/omni-directional hearing aid; Device
Lead sponsor: Vanderbilt University; Other
Eligibility: Not listed
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Multiple Sclerosis
Interventions: ADSTEP; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Vaccine Hesitancy, Communicable Diseases in Children
Interventions: Community Event, Educational Material; Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Interventions: MRTX849, TNO155; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 17
States / cities: Los Angeles, California • Orange, California • Chicago, Illinois + 9 more

Conditions: Oropharyngeal Cancer, HPV-Related Squamous Cell Carcinoma
Interventions: Gabapentin; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Sequencing

Buprenorphine Maintenance for Opioid Addicts - 3

Evaluating Efficacy of a Digital Game Therapeutic for Children With Autism

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

Understanding and Discouraging Overuse of Potentially Harmful Screening Tests

To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis

Behavioral Science Aspects of Rapid Test Acceptance

Healthy Hearts in the Heartland

Viral Infections in Healthy and Immunocompromised Hosts

Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease

Constraint-Induced (CI) Movement Therapy for Progressive Multiple Sclerosis (MS)

Outcome Following Hylan F- 20 (Synvisc) + Corticosteroid Injections for the Treatment of Osteoarthritis of the Knee

Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis

Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis

Transurethral Ultrasonic Imaging For Detection and Classification of Prostate Cancer

Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections

Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer

Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma

A Community-Based Strategy for Preventing Underage Drinking

Real-World Benefit From Directional Hearing Aids

A Randomized Controlled Trial of a Multicomponent Walking Aid Program for People With MS

Healthy, Immunized Communities Study

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing